BioLife Solutions, Inc. revised earnings guidance for the full year 2023. For the period, the company expects revenue at the low end of the previously announced guidance range of $144 million to $158 million, which assumes flat to modest sequential growth for its cell processing platform in the fourth quarter.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.53 USD | +3.97% | +10.53% | +7.88% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.88% | 794M | |
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+0.20% | 49.45B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.07% | 26.48B | |
+2.36% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- BLFS Stock
- News BioLife Solutions, Inc.
- BioLife Solutions, Inc. Revises Earnings Guidance for the Full Year 2023